about
Therapeutic Oligonucleotides Targeting Liver Disease: TTR AmyloidosisRNA mediated Toll-like receptor stimulation in health and diseaseHydrophobically Modified siRNAs Silence Huntingtin mRNA in Primary Neurons and Mouse BrainThe response of mammalian cells to double-stranded RNAInvestigating a New Generation of Ribozymes in Order to Target HCVStructural reorganization of the Toll-like receptor 8 dimer induced by agonistic ligandsVirtual Screening Approaches towards the Discovery of Toll-Like Receptor ModulatorsTargeted delivery of mutant tolerant anti-coxsackievirus artificial microRNAs using folate conjugated bacteriophage Phi29 pRNAlncRHOXF1, a Long Noncoding RNA from the X Chromosome That Suppresses Viral Response Genes during Development of the Early Human PlacentaSilencing disease genes in the laboratory and the clinicGene silencing: a therapeutic approach to combat influenza virus infections.SIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas.A novel high-throughput cell-based method for integrated quantification of type I interferons and in vitro screening of immunostimulatory RNA drug deliverysiRNA silencing of keratinocyte-specific GFP expression in a transgenic mouse skin model.Sequence-non-specific effects of RNA interference triggers and microRNA regulators.First siRNA library screening in hard-to-transfect HUVEC cells.Drug delivery-mediated control of RNA immunostimulationRNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT miceRational design of immunostimulatory siRNAs.X4 and R5 HIV-1 have distinct post-entry requirements for uracil DNA glycosylase during infection of primary cells.Self-assembled nanoparticles based on the c(RGDfk) peptide for the delivery of siRNA targeting the VEGFR2 gene for tumor therapy.RNAi and small interfering RNAs in human disease therapeutic applications.The role of PACT in mediating gene induction, PKR activation, and apoptosis in response to diverse stimuliTargets for future clinical trials in Huntington's disease: what's in the pipeline?Induced protein degradation: an emerging drug discovery paradigm.RNAi therapeutics: principles, prospects and challenges.RNA interference for improving the outcome of islet transplantation.8-Oxoguanosine switches modulate the activity of alkylated siRNAs by controlling steric effects in the major versus minor grooves.Analysis of Rex1 (zfp42) function in embryonic stem cell differentiation.In vivo efficacy and off-target effects of locked nucleic acid (LNA) and unlocked nucleic acid (UNA) modified siRNA and small internally segmented interfering RNA (sisiRNA) in mice bearing human tumor xenografts.Variables and strategies in development of therapeutic post-transcriptional gene silencing agentsA Potential of microRNAs for High-Content ScreeningImmune activation and target organ damage are consequences of hydrodynamic treatment but not delivery of naked siRNAs in mice.Increased expression of IRF4 and ETS1 in CD4+ cells from patients with intermittent allergic rhinitis.Hydrophobization and bioconjugation for enhanced siRNA delivery and targetingAtelocollagen-mediated systemic delivery prevents immunostimulatory adverse effects of siRNA in mammals.Vigilance and validation: Keys to success in RNAi screening.Metabolism, pharmacokinetics, tissue distribution, and stability studies of the prodrug analog of an anti-hepatitis B virus dinucleoside phosphorothioate.In vivo screening of modified siRNAs for non-specific antiviral effect in a small fish model: number and localization in the strands are importantRapid, cell-based toxicity screen of potentially therapeutic post-transcriptional gene silencing agents
P2860
Q26782089-3C8817DE-4313-467F-B857-CA23484D1D94Q26999252-69558E0A-95FE-4A64-AF9A-21ACF9DE47C7Q27317421-4876B88D-44D3-432E-B496-BB438F7708DFQ27481673-26C43DC5-6626-4B60-B7DC-D879AC5F0813Q27491032-01B31304-C138-4ECE-98E1-306F4EB7D7FEQ27684259-34A9DF25-10B7-4E1E-97CD-761B6342746DQ28068082-565E1EBF-71F0-4B43-928E-3EDA74291700Q28478596-26964980-EB87-4288-9277-98C973A4D0C7Q28601277-2A24EA89-9A74-4F36-91FF-57A85DBABF4FQ29039090-F44A7372-31B6-47A0-9805-D04BA4ABA0E7Q30370880-AD8C828B-A101-4B75-985B-BFF5B738BDEFQ33302103-D6CCAC5E-6EC7-46B6-8362-89F964B8D820Q33425353-0D1CD203-BF4F-47C7-9507-3A568CECA6B5Q33454280-0E030EC0-B982-4891-9F2F-FDABFCEF120BQ33566425-6D96AB1F-3591-4518-8E4A-D8AD496DB922Q33632140-3D6B19F3-3B93-46B7-9205-15A6EE548A3AQ33713938-2A534E9F-C428-4E50-8061-0747D35A62FFQ33730699-9DCE9153-8906-4593-9425-0431E4F2D11CQ33822185-FFA6BD83-36E0-445E-A718-1FDC0DC384A3Q33897859-25F57BFB-41C1-48F9-9D83-D841C44A1727Q34005639-2F5AE2F1-D4EE-4315-97F3-83BD3CDE5770Q34204092-ED404A34-D628-4588-BA14-35C880A43804Q34248644-D6DBBE63-54FB-4CC3-9F34-3A44A3C654F8Q34435001-1D070692-488B-4E43-A40D-7D5A368A33C2Q34545841-9B68CEC6-CD2C-4203-9875-57AB50773158Q34621268-A93A38B0-401C-4085-B299-959FC1AD23C2Q34729434-EA78E940-A626-42A7-9503-B1086E2A11CDQ34906848-671C25C4-05B6-4C85-A325-084130BA1512Q34995114-5B29383E-E551-4F6C-AB62-9B53ECFF8CA9Q35029194-2B2677D7-E6B5-4F2F-807D-476E3B7D0999Q35110219-B1D5594C-418D-438D-B66C-BCFC016BEB49Q35212807-0211F646-6EB7-480F-848F-088D8B5DF1E9Q35412231-0C9D59A6-4BF9-483B-9538-70A14FEF7D32Q35613678-47AA9402-EEFF-4DC7-9915-03DC9911361AQ35697443-F49F4032-FF46-463E-B432-CC5E2F61DE90Q35750040-13129CE7-263C-49BD-9FD4-E5390144AF3BQ35836004-D232CBE6-3384-4C2F-8D47-ECC19211CD17Q35913071-480C5807-E1EF-4B72-A2C8-1DE93B5CDB02Q36044790-6548FC51-5C48-405E-9389-24296FFE9566Q36073866-D099D92D-1ECC-4677-A20B-347839013D55
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Activation of the mammalian immune system by siRNAs.
@ast
Activation of the mammalian immune system by siRNAs.
@en
type
label
Activation of the mammalian immune system by siRNAs.
@ast
Activation of the mammalian immune system by siRNAs.
@en
prefLabel
Activation of the mammalian immune system by siRNAs.
@ast
Activation of the mammalian immune system by siRNAs.
@en
P2860
P356
P1433
P1476
Activation of the mammalian immune system by siRNAs
@en
P2093
Bryan R G Williams
P2860
P2888
P304
P356
10.1038/NBT1161
P577
2005-11-01T00:00:00Z